It is a common perception that privately-owned biotech firms seeking funding in the United States receive more money per round than their European counterparts. However, when comparing and analyzing the financing rounds of biotech companies working in the field of diagnostics and therapeutics for both geographies, it is clear that this is not the case. We looked at 156 financing rounds in Europe and 265 in the US over the past five years for biotech therapeutic and diagnostic companies, all of which are listed in the Life Science Nation database. For each data point, we had at least nine financing rounds.
The table below shows the average value by financing round in both the US and Europe over the last five years. In later financing rounds – especially series B, C, D and above – the average value is nearly identical in both the US and EU. We can see, from the table below that the largest variances in financing rounds come right at the beginning of the biotech’s life; in seed financing (61% higher in Europe) and Series A financing (46% lower in Europe).
To read the full, original article click on this link: Comparison of early stage funding in the US and EU – who gets more money? – Life Science Nation
